Meanwhile GLP-1 receptor agonists such as liraglutide (LEADER), semaglutide (SUSTAIN-6, PIONEER 6, SELECT), and dulaglutide (REWIND) demonstrated reduction in the risk of major adverse cardiovascular events (MACE) as well as stroke and cardiovascular risk. This evidence concerns the gene GLP1R and stroke disorder.